Cancer Cachexia Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | GTx, Akamis Bio, Centocor, Helsinn Therapeutics, Inc, Acacia Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cancer Cachexia pipeline constitutes 12+ key companies continuously working towards developing 15+ Cancer Cachexia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Cancer Cachexia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Cancer Cachexia Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/cancer-cachexia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cancer Cachexia Market.

Some of the key takeaways from the Cancer Cachexia Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Cancer Cachexia treatment therapies with a considerable amount of success over the years.

*
Cancer Cachexia companies working in the treatment market are GTx, Akamis Bio, Centocor, Inc., Helsinn Therapeutics (U.S.), Inc, Acacia Pharma Ltd, Helsinn Therapeutics, Novartis, Helsinn Therapeutics, Inc, Vicus Therapeutics, Florian Strasser, MD ABHPM, CSL Behring, Helsinn Therapeutics (U.S.), Inc, Pfizer, Janssen Research & Development, and others, are developing therapies for the Cancer Cachexia treatment

*
Emerging Cancer Cachexia therapies in the different phases of clinical trials are- GTx, Akamis Bio, Centocor, Inc., Helsinn Therapeutics (U.S.), Inc, Acacia Pharma Ltd, Helsinn Therapeutics, Novartis, Helsinn Therapeutics (U.S.), Inc, Vicus Therapeutics, Florian Strasser, MD ABHPM, CSL Behring, Helsinn Therapeutics (U.S.), Inc, Pfizer, Janssen Research & Development, and others are expected to have a significant impact on the Cancer Cachexia market in the coming years.

*
In August 2022, ARTHEx biotech has introduced ENTRY Trademark , a platform designed to enhance the development of its drug pipeline, which includes treatments for myotonic dystrophy, cancer cachexia, and osteoarthritis. This platform enables tissue-enriched delivery of antimiRs, facilitating the advancement of these drugs.

*
In June 2022, A team headed by Rutgers Cancer Institute of New Jersey has been awarded a USD 25 million Cancer Grand Challenges grant to investigate cancer cachexia, a debilitating condition frequently encountered by individuals in the advanced stages of cancer.

Cancer Cachexia Overview

Cancer cachexia is a complex syndrome characterized by severe body weight, fat, and muscle loss, and is often accompanied by anorexia (loss of appetite) and inflammation. This condition is commonly seen in patients with advanced cancer and significantly impacts their quality of life and overall prognosis.

Get a Free Sample PDF Report to know more about Cancer Cachexia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cancer-cachexia-pipeline-insight [https://www.delveinsight.com/report-store/cancer-cachexia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Cancer Cachexia Drugs Under Different Phases of Clinical Development Include:

*
GTx-024: GTx

*
MT-102: Akamis Bio

*
Infliximab; Gemcitabine: Centocor, Inc.

*
RC-1291: Helsinn Therapeutics (U.S.), Inc

*
APD209: Acacia Pharma Ltd

*
RC-1291 HCl: Helsinn Therapeutics

*
BYM338 active drug: Novartis Pharmaceuticals

*
RC-1291 HCl: Helsinn Therapeutics (U.S.), Inc

*
VT-122 low dose: Vicus Therapeutics

*
Lenalidomide: Florian Strasser, MD ABHPM

*
ALD518: CSL Behring

*
Anamorelin HCl: Helsinn Therapeutics (U.S.), Inc

*
GTx-024: GTx

*
ponsegromab: Pfizer

*
Xilonix: Janssen Research & Development

Cancer Cachexia Route of Administration

Cancer Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Cancer Cachexia Molecule Type

Cancer Cachexia Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Cancer Cachexia Pipeline Therapeutics Assessment

*
Cancer Cachexia Assessment by Product Type

*
Cancer Cachexia By Stage and Product Type

*
Cancer Cachexia Assessment by Route of Administration

*
Cancer Cachexia By Stage and Route of Administration

*
Cancer Cachexia Assessment by Molecule Type

*
Cancer Cachexia by Stage and Molecule Type

DelveInsight's Cancer Cachexia Report covers around 15+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Cancer Cachexia product details are provided in the report. Download the Cancer Cachexia pipeline report to learn more about the emerging Cancer Cachexia therapies [https://www.delveinsight.com/sample-request/cancer-cachexia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Cancer Cachexia Therapeutics Market include:

Key companies developing therapies for Cancer Cachexia are - NGM Biopharmaceuticals, Aveo Oncology, Aavogen Inc., Green Cross Wellbeing Corporation, Aeterna Zentaris, Aphios Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Helsinn Group, Merck KGaA, Artelo Biosciences Inc., Cannabics Pharmaceuticals Inc., TCI Peptide Therapeutics, Fresenius Kabi, Tetra Bio-Pharma, Actimed Therapeutics, and others.

Cancer Cachexia Pipeline Analysis:

The Cancer Cachexia pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Cancer Cachexia with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cancer Cachexia Treatment.

*
Cancer Cachexia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Cancer Cachexia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cancer Cachexia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cancer Cachexia drugs and therapies [https://www.delveinsight.com/sample-request/cancer-cachexia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of Cancer Cachexia Pipeline Drug Insight

*
Coverage: Global

*
Key Cancer Cachexia Companies: GTx, Akamis Bio, Centocor, Inc., Helsinn Therapeutics (U.S.), Inc, Acacia Pharma Ltd, Helsinn Therapeutics, Novartis, Helsinn Therapeutics (U.S.), Inc, Vicus Therapeutics, Florian Strasser, MD ABHPM, CSL Behring, Helsinn Therapeutics (U.S.), Inc, Pfizer, Janssen Research & Development, and others

*
Key Cancer Cachexia Therapies: GTx-024, MT-102, Infliximab; Gemcitabine, RC-1291, APD209, RC-1291 HCl, BYM338 active drug, RC-1291 HCl, VT-122 low dose, Lenalidomide, ALD518, Anamorelin HCl, GTx-024, ponsegromab, Xilonix, and others

*
Cancer Cachexia Therapeutic Assessment: Cancer Cachexia current marketed and Cancer Cachexia emerging therapies

*
Cancer Cachexia Market Dynamics: Cancer Cachexia market drivers and Cancer Cachexia market barriers

Request for Sample PDF Report for Cancer Cachexia Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/cancer-cachexia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Cancer Cachexia Report Introduction

2. Cancer Cachexia Executive Summary

3. Cancer Cachexia Overview

4. Cancer Cachexia- Analytical Perspective In-depth Commercial Assessment

5. Cancer Cachexia Pipeline Therapeutics

6. Cancer Cachexia Late Stage Products (Phase II/III)

7. Cancer Cachexia Mid Stage Products (Phase II)

8. Cancer Cachexia Early Stage Products (Phase I)

9. Cancer Cachexia Preclinical Stage Products

10. Cancer Cachexia Therapeutics Assessment

11. Cancer Cachexia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cancer Cachexia Key Companies

14. Cancer Cachexia Key Products

15. Cancer Cachexia Unmet Needs

16 . Cancer Cachexia Market Drivers and Barriers

17. Cancer Cachexia Future Perspectives and Conclusion

18. Cancer Cachexia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cancer-cachexia-pipeline-drugs-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-gtx-akamis-bio-centocor-helsinn-therapeutics-inc-acacia-pharma]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.